Advances in laboratory medicine最新文献_第2页

Detección de ADN del gen ompA de Chlamydia trachomatis en orina mediante amplificación isotérmica mediada por bucle (LAMP). 通过循环等温扩增（LAMP）检测尿液中沙眼衣原体ompA基因的DNA。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-05-29 eCollection Date: 2025-09-01 DOI: 10.1515/almed-2025-0061

Hemali Attanayake, Charitha Goonasekara, Nalaka Abeygunasekera, Jayanthi Elvitigala, Kamani Mangalika Gunasekera

引用次数: 0

Impacto del cálculo del valor seis sigma utilizando la ecuación de Schmidt-Launsbyn vs. la ecuación de Westgard en el programa español EQA tipo I. 使用Schmidt-Launsbyn方程与Westgard方程计算六西格玛值的影响。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-05-05 eCollection Date: 2025-09-01 DOI: 10.1515/almed-2024-0209

Fernando Marqués-García, Elisabeth González-Lao, Xavier Tejedor-Ganduxé, Beatriz Boned, Jorge Díaz-Garzón, Margarida Simón, Jose Vicente García-Lario, Carme Perich, María Pilar Fernández-Fernández, Luisa María Martínez-Sánchez, María Muñoz-Calero, Ricardo González-Tarancón, Pilar Fernández-Calle

引用次数: 0

Use of artificial intelligence to assess genetic predisposition to develop critical COVID-19 disease: a comparative study of machine learning models. 利用人工智能评估COVID-19关键疾病的遗传易感性：机器学习模型的比较研究

IF 1.1

Advances in laboratory medicine Pub Date : 2025-05-05 eCollection Date: 2025-06-01 DOI: 10.1515/almed-2025-0073

Salomón Martín Pérez, Flora Sanchez Jimenez, Sandra Fuentes Cantero, Marta Jímenez Barragan, Catalina Sanchez Mora, Juan M Borreguero Leon, Arrobas Velilla Teresa, Agustín Valido Morales, Juan A Delgado Torralbo, Antonio León Justel

{"title":"Use of artificial intelligence to assess genetic predisposition to develop critical COVID-19 disease: a comparative study of machine learning models.","authors":"Salomón Martín Pérez, Flora Sanchez Jimenez, Sandra Fuentes Cantero, Marta Jímenez Barragan, Catalina Sanchez Mora, Juan M Borreguero Leon, Arrobas Velilla Teresa, Agustín Valido Morales, Juan A Delgado Torralbo, Antonio León Justel","doi":"10.1515/almed-2025-0073","DOIUrl":"10.1515/almed-2025-0073","url":null,"abstract":"Objectives: Early prediction of critical COVID-19 disease is crucial for an optimal clinical management. The objective of this study was to optimize predictive models for critical COVID-19 disease. Clinical data, laboratory data and genetic polymorphisms were integrated into AI models to compare the performance of different machine learning algorithms.Methods: Data from 155 inpatients were analyzed, 23 of whom developed critical disease. A univariate analysis was performed to assess potential correlations between seven SNPs, nine clinical variables and 10 laboratory parameters at admission.Results: Of the 7 SNPs, only three SNPs demonstrated a significant association with critical disase, namely: rs77534576, rs10774671 and rs10490770. The ensemble models exhibited the best performance: Random Forest (AUC=0.989), XGBoost (AUC=0.954) and AdaBoost (AUC=0.927). Variable importance varied across models, with age, C-reactive protein, heart diseases and the three SNPs being the most influential features. The predictive power of models improved with the integration of the three SNPs, as compared to previous studies where genetic data were not included. Internal validation confirmed the superiority and stability of the ensemble models.Conclusions: Machine learning models may help predict progression into critical COVID-19-disease. The predictive power of models improves when SNPs associated with COVID-19 severity are integrated with laboratory and clinical data. Prior to implementation in clinical practice, larger studies in different populations are needed to validate and support the generalization of these results.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"6 2","pages":"181-189"},"PeriodicalIF":1.1,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-time immunophenotypic shifts in pediatric B lymphoblastic leukemia providing implications for minimal residual disease detection. 儿童B淋巴细胞白血病的实时免疫表型变化提供了最小残留疾病检测的意义。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-05-05 eCollection Date: 2025-09-01 DOI: 10.1515/almed-2024-0202

Omer Javed, Neelum Mansoor, Naeem Jabbar, Hamza Khan, Talha Israr, Sidra Maqsood, Saba Jamal, Fatima Meraj

{"title":"Real-time immunophenotypic shifts in pediatric B lymphoblastic leukemia providing implications for minimal residual disease detection.","authors":"Omer Javed, Neelum Mansoor, Naeem Jabbar, Hamza Khan, Talha Israr, Sidra Maqsood, Saba Jamal, Fatima Meraj","doi":"10.1515/almed-2024-0202","DOIUrl":"10.1515/almed-2024-0202","url":null,"abstract":"Objectives: Disease monitoring in acute leukemia management is crucial for risk stratification and chemotherapy response assessment. Minimal residual disease (MRD) testing is the most reliable tool, measuring antigenic expression differences between leukemic cells, hematogones, and mature benign B-cells. Modulation of antigen expression during treatment under chemotherapeutic drugs may complicate MRD analysis and detection. The present study investigates immunophenotypic modulation (IM) during chemotherapy phases in children with acute lymphoblastic leukemia (B-ALL), using a modified BFM protocol, and its potential implications for MRD detection.Methods: The study was conducted at the Hematology Department, Indus Hospital and Health Network, Karachi. All MRD positive cases of pediatric B-ALL (1 month -16 years of age) were included, from April 2019- March 2022. MRD was done on bone marrow aspirate using 8-color flow cytometry. The data from 203 patients, who were MRD positive in bone marrow throughout the evaluation period was considered. The IM was assessed by comparative analysis of the changes in mean fluorescence intensity (MFI) of nine highly relevant antigens expressed by the leukemic cells.Results: Statistically significant changes in the MFI levels of antigens were observed in leukemic blasts and mature benign B-cells. All the analyzed samples revealed IM to different extents. Our results confirm the presence of immunophenotypic changes for CD10, CD19, CD34, CD45, TdT, and CD66 during chemotherapy.Conclusions: Measuring the MRD assists in monitoring the disease, however, IM of the different antigens expressed by the leukemic blasts should be considered and cautiously analyzed to prevent erroneous results.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"6 3","pages":"358-364"},"PeriodicalIF":1.1,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of urine albumin-to-creatinine ratio analysis using strip test as a screening method for urinary albumin determination in primary care. 尿白蛋白与肌酐比值分析在初级保健中作为尿白蛋白测定筛查方法的评价。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-05-01 eCollection Date: 2025-09-01 DOI: 10.1515/almed-2024-0068

Paula Liébanas García, Silvia Montolio Breva, Teresa Sans Mateu

{"title":"Evaluation of urine albumin-to-creatinine ratio analysis using strip test as a screening method for urinary albumin determination in primary care.","authors":"Paula Liébanas García, Silvia Montolio Breva, Teresa Sans Mateu","doi":"10.1515/almed-2024-0068","DOIUrl":"10.1515/almed-2024-0068","url":null,"abstract":"Objectives: The determination of urinary albumin, crucial for chronic kidney disease (CKD) diagnosis and monitoring, typically employs quantitative techniques as the gold standard. However, semi-quantitative methods such as urine reagent strips show promise as cost-effective and rapid screening tools. This study aims to evaluate the feasibility of utilizing Meditape UC-11A strips (Sysmex, Kobe, Japan) for albuminuria screening compared to quantitative assays measuring urine albumin-to-creatinine ratio (ACR).Methods: We systematically analyzed 1,627 strip samples using Meditape UC-11A strips whenever quantitative urinary albumin measurement was required. We compared the ACR measured by strip test with the gold standard (quantitative method determined by Atellica, Siemens, Marburg, Germany) and calculated diagnostic indicators. Additionally, we assessed the economic implications based on test prices (€2.88 for quantitative albumin plus creatinine, and €0.93 for a Meditape UC-11A strip).Results: Receiver operator characteristic (ROC) curve analysis was conducted to determine the optimal cut-off point. The concordance rate achieved using the calculated cut-off point was 90.78 %. Using the quantitative test as the gold standard, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ACR, analyzed using Meditape UC-11A, were 84.2 , 91.9, 62.7, and 97.3 %, respectively. Our findings suggest a potential saving of 81.2 % on quantitative tests during the study period, amounting to €2,291.65.Conclusions: This study supports the use of Meditape UC-11A strips for detecting abnormal levels of albuminuria, thus offering a viable alternative to quantitative measurement methods. Substantial cost savings can be achieved through this approach.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"6 3","pages":"345-350"},"PeriodicalIF":1.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating ctDNA testing for EGFR analysis in advanced non-small cell lung cancer: strategies for clinical laboratories. 将ctDNA检测整合到晚期非小细胞肺癌的EGFR分析：临床实验室策略

IF 1.1

Advances in laboratory medicine Pub Date : 2025-05-01 eCollection Date: 2025-09-01 DOI: 10.1515/almed-2025-0012

Esther Fernández-Galán, Joan Anton Puig-Butillé

{"title":"Integrating ctDNA testing for EGFR analysis in advanced non-small cell lung cancer: strategies for clinical laboratories.","authors":"Esther Fernández-Galán, Joan Anton Puig-Butillé","doi":"10.1515/almed-2025-0012","DOIUrl":"10.1515/almed-2025-0012","url":null,"abstract":"Epidermal growth factor receptor gene (EGFR) molecular testing is essential for guiding targeted therapies in patients with advanced non-small cell lung cancer (NSCLC). Between 15 and 40 % of patients with NSCLC carry mutations in EGFR that are sensitive to tyrosine kinase inhibitors (TKIs). Due to the significant clinical benefits, identifying patients eligible for TKI therapy is crucial for optimizing treatment. While tumor tissue has been considered the gold standard for this testing, adequate material for EGFR molecular study cannot be obtained in up to 30 % of patients. In this context, circulating tumor DNA (ctDNA) analysis offers a guideline-recommended non-invasive method to detect EGFR mutations. Despite its promise, the widespread adoption of ctDNA analysis faces challenges for integration into clinical practice. This review provides a comprehensive synthesis of current knowledge on the clinical utility of EGFR molecular analysis in ctDNA, alongside its relationship with other circulating biomarkers widely implemented in clinical laboratories, such as serum tumor markers (STMs). It delves into the technical considerations, interpretation of results, and other challenges associated with ctDNA analysis, offering valuable insights into its integration into laboratory workflows.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"6 3","pages":"233-244"},"PeriodicalIF":1.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of external quality assessment in extra-analytical phases in clinical laboratories in Spain: a survey by the Spanish Society of Laboratory Medicine (SEQC^ML). 在西班牙临床实验室的分析外阶段使用外部质量评估：西班牙检验医学学会（SEQCML）的一项调查。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-04-21 eCollection Date: 2025-06-01 DOI: 10.1515/almed-2025-0067

Andrea Caballero Garralda, Immaculada Comas Reixach, Carlos García Miralles, Rubén Gómez Rioja, María Antonia Llopis Díaz, Débora Martínez Espartosa, Reyes Nicolás de Blas, Mariona Panadès Turró, Laura Puigví Fernández, Laura Rodelgo Jiménez, Berta Sufrate-Vergara, Emma Ventura Orriols

{"title":"Use of external quality assessment in extra-analytical phases in clinical laboratories in Spain: a survey by the Spanish Society of Laboratory Medicine (SEQCML).","authors":"Andrea Caballero Garralda, Immaculada Comas Reixach, Carlos García Miralles, Rubén Gómez Rioja, María Antonia Llopis Díaz, Débora Martínez Espartosa, Reyes Nicolás de Blas, Mariona Panadès Turró, Laura Puigví Fernández, Laura Rodelgo Jiménez, Berta Sufrate-Vergara, Emma Ventura Orriols","doi":"10.1515/almed-2025-0067","DOIUrl":"10.1515/almed-2025-0067","url":null,"abstract":"Objectives: Quality indicators (QIs) are a valuable tool for monitoring and improving extra-analytical phase performance in the clinical laboratory (CL). For that reason, the Spanish Society of Laboratory Medicine (SEQCML) launched its Pre-analytical Phase EQA Program in 2001.Methods: In 2023, a survey was conducted to assess the level of participation in the EQA Program, identify its potential improvements, and enhance the understanding of the collection and estimation processes of the extra-analytical QI.Results: In total, 51 % of respondents (124 responses in total) were enrolled in the program. The primary reason for participating was the need of monitoring of the extra-analytical phases (38 %). In contrast, the main reason for not taking part in the EQA Program was the difficulty in collecting data (32 %). As to potential points for improvement, 56 % considered that QI should be analyzed disaggregated by type of extraction (ambulatory vs. urgent). As many as 86 % of respondents would be interested in participating in a post-analytical phase EQA Program. Most of the suggestions about indicators to be included were related to events regarding temperature and transport times from peripheral extraction sites.Conclusions: Although interest in QIs for pre- and post-analytical phases is growing, the percentage of laboratories that collect data regularly is still limited. The findings of this survey have led the future directions for the EQA Pre-analytical Program, updating and adapting it to the current needs of CLs.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"6 2","pages":"199-205"},"PeriodicalIF":1.1,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Necesidad de ajustar al IMC los valores límite de los péptidos natriuréticos para un diagnóstico más personalizado de la insuficiencia cardíaca. 需要调整BMI钠肽限值，以更个性化地诊断心力衰竭。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-04-18 eCollection Date: 2025-09-01 DOI: 10.1515/almed-2025-0060

Damien Gruson, Sergio Bernardini, Marco Perrone

引用次数: 0

Ciencia de datos aplicada a la obtención de estimados de variación biológica. 应用于获得生物变异估计的数据科学。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-04-03 eCollection Date: 2025-06-01 DOI: 10.1515/almed-2024-0163

Fernando Marques-Garcia, Ana Nieto-Librero, Nerea Gonzalez-García, Xavier Tejedor-Ganduxé, Cristina Martinez-Bravo

引用次数: 0

Uso de la evaluación externa de la calidad en las fases extraanalíticas de los laboratorios clínicos españoles: una encuesta de la Sociedad Española de Medicina de Laboratorio (SEQC^ML). 外部质量评估在西班牙临床实验室分析外阶段的使用：西班牙实验室医学学会（SEQCML）的一项调查。

IF 1.1

Advances in laboratory medicine Pub Date : 2025-04-03 eCollection Date: 2025-06-01 DOI: 10.1515/almed-2024-0160

Andrea Caballero Garralda, Immaculada Comas Reixach, Carlos García Miralles, Rubén Gómez Rioja, María Antonia Llopis Díaz, Débora Martínez Espartosa, Reyes Nicolás de Blas, Mariona Panadès Turró, Laura Puigví Fernández, Laura Rodelgo Jiménez, Berta Sufrate-Vergara, Emma Ventura Orriols

引用次数: 0